A Study of Pentasa in Patients With Ulcerative Colitis

Ferring

Status: Completed

Conditions: Ulcerative Colitis

Study type: Observational

Funder types: Industry

Identifiers

NCT01104753

FE999907 CS07

Details and patient eligibility

About

Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).

Enrollment: 338 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients suffering from ulcerative colitis

Exclusion criteria

• Hypersensitivity to mesalazine, salicylates or to any excipient
• Severe damage to liver or renal functions

Trial design

338 participants in 1 patient group

Non-interventional post-authorisation safety study